Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.80 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.80 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.80 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.76 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7249809 | 0.90 | CYP19A1 (0.80) | CYP24A1CYP26A1CYP19A1CYP27A1DRD2 | |
| SCHEMBL6827615 | 0.89 | CYP19A1 (1.00) | CYP24A1CYP26A1CYP19A1CYP27A1 | |
| SCHEMBL8159828 | 0.89 | CYP26A1 (0.78) | CYP24A1CYP26A1CYP19A1CYP27A1DRD2 | |
| SCHEMBL5582351 | 0.88 | CYP19A1 (0.77) | CYP24A1CYP26A1CYP19A1CYP27A1ACHE | |
| SCHEMBL6822323 | 0.87 | CYP19A1 (0.76) | CYP24A1CYP26A1CYP19A1CYP27A1DRD2 | |
| SCHEMBL8203668 | 0.87 | CYP26A1 (0.79) | CYP24A1CYP26A1CYP19A1CYP27A1ACHE | |
| SCHEMBL4623145 | 0.87 | CYP24A1 (0.66) | CYP24A1CYP26A1CYP19A1CYP27A1DRD2 | |
| SCHEMBL28733982 | 0.85 | CYP24A1 (0.66) | CYP24A1CYP26A1CYP19A1CYP27A1SIGMAR1 | |
| SCHEMBL29679457 | 0.85 | CYP24A1 (0.66) | CYP24A1CYP26A1CYP19A1CYP27A1SIGMAR1 | |
| SCHEMBL15874727 | 0.85 | CYP24A1 (0.66) | CYP24A1CYP26A1CYP19A1CYP27A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
| US-6133286-A | ANTAGONISTS; ANTIINFLAMMATORY AGENTS FOR RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, PSORIASIS AND OTHER SKIN DISORDERS, E.G., ECZEMA, ERYTHEMA, PRURITUS AND ACNE; STROKE, REPERFUSION INJURY, GRAFTING | PFIZER INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6117874-A | AROMATIC RING-SUBSTITUTED 4-HYDROXYTETRAHYDROQUINOLINES | PFIZER INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6051601-A | USEFUL OF INFLAMMATORY DISORDERS INCLUDING RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, PSORIASIS AND OTHER SKIN DISORDERS SUCH AS ECZEMA, ERYTHEMA, PRURITUS AND ACNE, STROKE AND OTHER FORMS OF REPERFUSLON | PFIZER INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5939452-A | TREATMENT OF ANTIINFLAMMATORY SKIN DISORDERS, AUTOIMMUNE DISORDERS | PFIZER INC (US) | 1999-08-17 | — | — | US | disclosed |
| EP-0785935-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4' (LTB4) ANTAGONISTS | PFIZER INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| EP-0785930-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B 4? (LTB 4?) ANTAGONISTS | PFIZER INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011925-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4' (LTB4) ANTAGONISTS | PFIZER INC. (US) | 1996-04-25 | — | — | WO | disclosed |
| WO-1996011920-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4 (LTB4) ANTAGONISTS | PFIZER INC. (US) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | CYP24A1 1214/4885CYP26A1 2627/4885CYP19A1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.